1Li B, An HJ, Kirmiz C, Lebfilla CB et al.Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins [J]. J Proteome Res, 2008, 7 (9): 3776-3788.
2Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management[J]. Drug Saf, 2005,28 ( 5 ) :401-416.
3Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ [ J ]. A JOG, 2007, 197 : 340-345.
4Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration, safety issues and controversies[J]. J Sex Med. 2007,4(4 Pt 1 ) :859- 866.
5Lutgendorf SK, Anderson B, Rothrock N. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer[J]. 89 (6) : 1402-1411.
6Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease[J]. Oncologist ,2002, 7( suppl 5 ) :20-28.
7Chan YM, Ngan YH, Li BY, et al. A longitudinal study on quality of life after gynecologic cancer treatment [J]. Gynecol Oncol,2001, 83(1) :10-19.
8Andersen BL, Woods XA, Copeland LJ. Sexual self-schem and sexual morbidity among gynaecologic cancer survivors [J]. J Consult Clin Psychol, 1997, 65:221-229.
9Lacey JV, Brinton LA, Bame WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix [J]. Gynecol Oncol,2000,77 : 149 154.
10Garg PP, Kerlikowske K, Subak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis[J]. Obstet Gynecol, 1998,92:472-479.
